Kura Oncology Inc. has presented its latest developments at the ASCO Investor Presentation, focusing on its investigational therapy for Acute Myeloid Leukemia $(AML.AU)$. The presentation highlighted the significant unmet needs in AML treatment, with approximately 22,010 new cases diagnosed annually in the United States and a 5-year survival rate of 33%. Kura Oncology's investigational drug, Ziftomenib, is a targeted menin inhibitor for relapsed/refractory and newly-diagnosed AML. The New Drug Application for Ziftomenib is based on positive results from the Phase 2 KOMET-001 trial and has been granted Priority Review with a Prescription Drug User Fee Act target action date set for November 30, 2025. You can access the full presentation through the link below.